4D Molecular Therapeutics, Inc. (FDMT) vs Solid Biosciences Inc. (SLDB)

4D Molecular Therapeutics, Inc. and Solid Biosciences Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Solid Biosciences Inc. are of similar size ($807.1M and $802.0M). Solid Biosciences Inc. has the higher net margin (0.00% vs −194.7%) and the higher return on invested capital (0.00% vs −186.9%). Across the 16 metrics below, 4D Molecular Therapeutics, Inc. leads on 8 and Solid Biosciences Inc. on 8.

Valuation

Metric FDMT SLDB Biotechnology median
P/E n/m n/m 7.88
P/S 11.05 93.13 11.47
P/B 2.49 2.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 7.34 59.52 10.73
Earnings yield (18.18%) (26.20%) (28.84%)
Free cash flow yield (15.34%) (17.92%) (23.03%)

Profitability

Metric FDMT SLDB Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (214.24%) 0.00% 0.00%
Net margin (194.74%) 0.00% 0.00%
Free cash flow margin (169.51%) 0.00% 0.00%
Return on equity (43.25%) (65.50%) (57.72%)
Return on assets (37.09%) (56.83%) (49.22%)
Return on invested capital (186.91%) 0.00% 0.00%

Growth

Metric FDMT SLDB Biotechnology median
Revenue growth (TTM) 278,712.12% — 5.64%
EPS growth (last fiscal year) 18.79% 34.97% —
Revenue growth, 5-year CAGR 44.32% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FDMT SLDB Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 8.03 13.82 4.73
Net debt to EBITDA 2.52 1.05 0.96

Dividend

Metric FDMT SLDB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FDMT SLDB Biotechnology median
Market cap 807.12m 802.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack